1-4 of 4
Wijith Munasinghe, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 2 Study of Venetoclax Plus Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Luciano J Costa, MD PhD, Edward A. Stadtmauer, MD FACP, Gareth Morgan, MD, Gregory Monohan, MD, Tibor Kovacsovics, MD, Nicholas Burwick, MD, Andrzej Jakubowiak, MD PhD, Jonathan L Kaufman, MD, Mehrdad Mobasher, MD MPH, Kevin J. Freise, PhD, Jeremy A. Ross, PhD, John Pesko, PhD, Wijith Munasinghe, PhD, Saketh Gudipati, MD, Sarah Mudd, PhD, Orlando Bueno, MD PhD, Shaji K. Kumar, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 303.
https://doi.org/10.1182/blood-2018-99-117026
Published: 2018
Journal Articles

Deep and Durable Responses Following Venetoclax (ABT-199 / GDC-0199) Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from a Phase 1b Study

Shuo Ma, MD, Danielle M. Brander, MD, John F. Seymour, MBBS, PhD, Thomas J. Kipps, MD PhD, Jacqueline C. Barrientos, MD, Matthew S. Davids, MD, Mary Ann Anderson, MBBS, Michael Y. Choi, MD, Constantine S. Tam, MBBS, Tanita Mason-Bright, Betty Prine, Wijith Munasinghe, PhD, Ming Zhu, PhD, Su Young Kim, MD, Rod A. Humerickhouse, MD PhD, Andrew W. Roberts, MBBS, PhD
Journal: Blood
Blood (2015) 126 (23): 830.
https://doi.org/10.1182/blood.V126.23.830.830
Published: 2015
Journal Articles

Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 1b Results

Philippe Moreau, MD PhD, Asher Chanan-Khan, MD, Andrew W. Roberts, MBBS, PhD, Amit B. Agarwal, MDPhD, Thierry Facon, Shaji Kumar, MD, Cyrille Touzeau, MD, David Darden, MS, Lura Morris, BA, Jeremy Ross, PhD, Ahmed H Salem, PhD, Wijith Munasinghe, PhD, Ming Zhu, PhD, Joel Leverson, PhD, Paulo Maciag, MD, Sari Heitner Enschede, MD, Maria Verdugo, MD, Rod A. Humerickhouse, MD PhD, Simon Harrison, MD
Journal: Blood
Blood (2015) 126 (23): 3038.
https://doi.org/10.1182/blood.V126.23.3038.3038
Published: 2015
Journal Articles

Determination of Recommended Phase 2 Dose of ABT-199 (GDC-0199) Combined with Rituximab (R) in Patients with Relapsed / Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Andrew W. Roberts, MBBS, PhD, Shuo Ma, MD PhD, Danielle M. Brander, MD, Thomas J. Kipps, MD PhD, Jacqueline C. Barrientos, MD, Matthew S. Davids, MD, Mary Ann Anderson, PhD, Constantine Tam, MD, Tanita Mason-Bright, Nikita K. Rudersdorf, Lori Gressick, BS, Jianning Yang, PhD, Wijith Munasinghe, PhD, Ming Zhu, PhD, Elisa Cerri, MD, Sari H. Enschede, MD, Rod A. Humerickhouse, MD PhD, John F Seymour, MBBS, FRACP, PhD
Journal: Blood
Blood (2014) 124 (21): 325.
https://doi.org/10.1182/blood.V124.21.325.325
Published: 2014